Please assess the completion status of the following clinical trial:

Trial Title: Aspirin Attenuates Inflammation in Human Cerebral Aneurysms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age 18-80 years.~2. Incidental (non-ruptured) IA ≥5 mm.~3. Treating neurosurgeon and patient agree on observation period of 3 months before proceeding with treatment either endovascularly or by microsurgical clipping.~4. Positive MRI signal change corresponding of ferumoxytol uptake is observed.~5. No history of aspirin intake or NSAIDs for 4 weeks prior to enrolment.~6. No current history of statin use.~Exclusion Criteria:~1. Patients with treated IAs (by coil embolization or surgical clipping) will be excluded.~2. Patients presenting with ruptured intracranial IAs will also be excluded from the study, to avoid interfering with timely treatment of ruptured IAs.~3. Children~4. pregnant women~5. persons with history of allergy or hypersensitivity to iron or dextran or iron-polysaccharide preparations~6. patients requiring monitored anesthesia or intravenous (IV) sedation for MR imaging~7. patients with contraindication to MRI~8. patients with renal insufficiency, hepatic insufficiency or iron overload, 9. patients receiving combination antiretroviral therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- aspirin (Type: EXPERIMENTAL): aspirin 81 mg po every day
- no aspirin (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).